Merck & Co., Inc. (MRK) Projected to Announce Quarterly Earnings on Tuesday

Key Points

• Merck is expected to report Q2 2026 results before the market opens on August 4. Analysts forecast a loss of $0.26 per share on $16.35 billion in revenue, while full-year EPS guidance is $5.04–$5.16.
• In its previous quarter, Merck beat consensus estimates with a loss of $1.28 per share versus expectations of $1.47, while revenue rose 4.9% year over year to $16.29 billion.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $133.94. Merck recently paid a quarterly dividend of $0.85 per share, equivalent to a 2.5% yield.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Merck & Co., Inc. to post earnings of ($0.26) per share and revenue of $16.3492 billion for the quarter. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Interested persons are encouraged to explore the company's upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 9:00 AM ET.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the business earned $2.22 EPS. The business's revenue was up 4.9% on a year-over-year basis. On average, analysts expect Merck & Co., Inc. to post $3 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $134.09 on Tuesday. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $133.82. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company has a market capitalization of $331.17 billion, a price-to-earnings ratio of 37.74, a price-to-earnings-growth ratio of 5.20 and a beta of 0.19. The firm's fifty day moving average price is $122.03 and its 200 day moving average price is $117.94.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were paid a dividend of $0.85 per share. The ex-dividend date was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 95.77%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on MRK shares. Weiss Ratings lowered Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research report on Friday, May 15th. Cantor Fitzgerald reissued a "neutral" rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a report on Monday, July 6th. UBS Group raised their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Scotiabank lifted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a report on Tuesday, June 30th. Finally, Wall Street Zen lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $133.94.

Institutional Trading of Merck & Co., Inc.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC grew its position in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock worth $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock valued at $910,000 after acquiring an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC raised its position in shares of Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock valued at $2,590,000 after acquiring an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC raised its position in shares of Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock valued at $3,054,000 after acquiring an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock worth $53,918,000 after purchasing an additional 359,356 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source